Alanine Transaminase
Research News and Information

Friday, March 19, 2010

Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico-pathological analysis.

13 Dec 2009 BACKGROUND: Vincristine (VCR) and actinomycin D (ACD) form the backbone of chemotherapeutic regimens of Wilms tumor treatment. Veno-occlusive disease (VOD) is a potentially life-threatening complication of ACD. OBJECTIVES: To investigate the ... Read more...

Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.

30 Oct 2009 OBJECTIVES: Recent studies have suggested that highly active antiretroviral therapy may lead to rises in alanine transaminase (ALT) among HIV-infected patients. However, the definition of an ALT flare is arbitrary and the extent to which such ... Read more...

Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis.

5 Oct 2009 AIM: To investigate the correlation between the antifibrotic effect of baicalin and serum cytokine production in rat hepatic fibrosis. METHODS: Forty male Sprague-Dawley rats were divided randomly into four groups: normal control group, model group, ... Read more...

Latest indexed articles for 'Alanine Transaminase'

These are the very latest articles for this heading:

• Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico-pathological analysis. 13 Dec 2009
• Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. 30 Oct 2009
• Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis. 5 Oct 2009
• Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. 29 Sep 2009
• Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. 29 Sep 2009
• Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. 29 Sep 2009
• Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. 29 Sep 2009
• Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. 29 Sep 2009
• Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor alpha, but not human PPARalpha. 10 Sep 2009
• Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. 9 Sep 2009
• Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. 8 Sep 2009
• [Elevation of liver enzymes in a patient with chronic hepatitis B during alpha-interferon treatment: what is it all about?] 8 Sep 2009
• Helicobacter pylori promotes hepatic fibrosis in the animal model. 5 Sep 2009
• Hepatoprotection of chlorella against carbon tetrachloride-induced oxidative damage in rats. 30 Aug 2009
• Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia. 30 Aug 2009
• [Prevalence of pancreatic cancer in diabetics and clinical characteristics of diabetes-associated with pancreatic cancer--comparison between diabetes with and without pancreatic cancer] 30 Aug 2009
• [Changes in liver stiffness after acute or chronic liver injury due to viral hepatitis--does fibrosis exist after recovery from acute viral hepatitis?] 30 Aug 2009
• Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD). 30 Aug 2009
• An unusual complication: prolonged myopathy due to an alternative medical therapy with heat and massage. 30 Aug 2009
• Hepcidin in acute iron toxicity. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Alanine Transaminase'

Definition: An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.

Chemical name: L-Alanine:2-oxoglutarate aminotransferase

Registry Number: EC 2.6.1.2

Descriptor UI: D000410

Alternative terms: Alanine Transaminase; Transaminase, Alanine; Glutamic-Alanine Transaminase; Glutamic Alanine Transaminase; Transaminase, Glutamic-Alanine; Alanine-2-Oxoglutarate Aminotransferase; Alanine 2 Oxoglutarate Aminotransferase; Aminotransferase, Alanine-2-Oxoglutarate; Alanine Aminotransferase; Aminotransferase, Alanine; Glutamic-Pyruvic Transaminase; Glutamic Pyruvic Transaminase; Transaminase, Glutamic-Pyruvic; SGPT;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Tree Number: D08.811.913.477.700.100;

History Note: 98(66)

Technical Notes: /blood = SGPT /blood (not just SGPT)